Lilly begins phase 3 clinical trial with baricitinib for hospitalized coronavirus patientsChristian Fernsby ▼ | June 19, 2020
Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo‑controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with coronavirus.
Trial Eli Lilly
Lilly expects to enroll 400 patients in the trial, with data expected in the next few months.
The study will be conducted in the U.S., Europe and Latin America and includes patients hospitalized with SARS-CoV-2 infection who have at least one elevated marker of inflammation but do not require invasive mechanical ventilation at study entry. ■